Ftse Mib
36.267,63
1,25%
DAX
20.903,39
1,31%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
103.148,20
-0,94%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ARS Pharmaceuticals Inc (SPRY) ARS Pharmaceuticals Inc (SPRY) Notizie

ARS Pharmaceuticals Inc

SPRY
12,57
0,39 (3,20%)
18 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/1/202514:08EDGAR2Form 8-K - Current report
13/1/202514:00GLOBEARS Pharmaceuticals Announces Preliminary Fourth Quarter..
06/1/202514:00GLOBEARS Pharmaceuticals Files for Approval of neffy® in Canada..
19/12/202423:25GLOBEARS Pharmaceuticals Announces neffy® (Epinephrine Nasal..
19/12/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202414:00GLOBEARS Pharmaceuticals to Participate in the 43rd Annual J.P...
14/12/202401:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202423:24EDGAR2Form 144 - Report of proposed sale of securities
12/12/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202423:02EDGAR2Form 144 - Report of proposed sale of securities
12/12/202420:32GLOBEARS Pharmaceuticals Announces Filings for Approval of neffy®..
12/12/202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/12/202422:48EDGAR2Form 144 - Report of proposed sale of securities
09/12/202423:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/12/202401:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202423:30EDGAR2Form 144 - Report of proposed sale of securities
06/12/202422:05EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
05/12/202423:06EDGAR2Form 144 - Report of proposed sale of securities
05/12/202403:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202403:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202423:46EDGAR2Form 144 - Report of proposed sale of securities
04/12/202423:15EDGAR2Form 144 - Report of proposed sale of securities
04/12/202414:00GLOBEARS Pharmaceuticals Announces Planned Launch of..
03/12/202423:25EDGAR2Form 144 - Report of proposed sale of securities
03/12/202401:01EDGAR2Form 144 - Report of proposed sale of securities
02/12/202422:42EDGAR2Form 144 - Report of proposed sale of securities
27/11/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202421:21EDGAR2Form 144 - Report of proposed sale of securities
14/11/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202413:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202413:00EDGAR2Form 8-K - Current report
13/11/202412:30GLOBEARS Pharmaceuticals Reports Third Quarter 2024 Financial..
12/11/202414:01EDGAR2Form 8-K - Current report
11/11/202413:00GLOBEARS Pharmaceuticals Announces Exclusive Agreement with..
06/11/202414:00GLOBEARS Pharmaceuticals Announces Conference Call and Webcasts..
24/10/202414:30GLOBEARS Pharmaceuticals Showcases Intranasal Epinephrine Data at..
17/10/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/10/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202422:01EDGAR2Form 144 - Report of proposed sale of securities
15/10/202417:28EDGAR2Form 144 - Report of proposed sale of securities
15/10/202413:02EDGAR2Form 8-K - Current report
10/10/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202422:15EDGAR2Form 8-K - Current report
23/9/202414:00GLOBEARS Pharmaceuticals Announces U.S. Availability of neffy®..
19/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202422:06EDGAR2Form 144 - Report of proposed sale of securities
12/9/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/9/202422:05GLOBEARS Pharmaceuticals to Participate in the 2024 Cantor Global..
Apertura: 12,26 Min: 12,19 Max: 12,9899
Chiusura: 12,18

La tua Cronologia

NASDAQ
SPRY
ARS Pharmaceuticals
USOTC
BLEG
Branded Legacy (PK)
LSE
POW
Power Metal Resources
NASDAQ
LUCD
Lucid Diagnostics
BOV
PATI3
PANATLANTICA ON
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network